Buscar
Briacell Therapeutics Corp
BCTXAñadir a la lista de seguimiento
3.440USD
-0.190-5.23%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
24.94MCap. mercado
PérdidaP/E TTM
Más Datos de Briacell Therapeutics Corp Compañía
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Información de Briacell Therapeutics Corp
Símbolo de cotizaciónBCTX
Nombre de la empresaBriacell Therapeutics Corp
Fecha de salida a bolsaOct 12, 2006
Director ejecutivoWilliams (William V)
Número de empleados22
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 12
DirecciónSuite 300 - Bellevue Centre, 235 -15th Street
CiudadWEST VANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV7T 2X1
Teléfono16049211810
Sitio Webhttps://briacell.com/
Símbolo de cotizaciónBCTX
Fecha de salida a bolsaOct 12, 2006
Director ejecutivoWilliams (William V)
Ejecutivos de Briacell Therapeutics Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.90K
+98.69%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
56.52K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
28.27K
+99.94%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
28.26K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
66.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.90K
+98.69%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
56.52K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
28.27K
+99.94%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
28.26K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
66.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Briacell Therapeutics Corp?
Los cinco principales accionistas de Briacell Therapeutics Corp son: Dr. William V. Williams, M.D.
¿Cuántas instituciones poseen acciones de Briacell Therapeutics Corp (BCTX)?
A fecha de 2026Q1, 52 instituciones poseen acciones de Briacell Therapeutics Corp, con un valor de mercado combinado de aproximadamente 155.47K, lo que representa el 2.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -64567.00.